Non-adherence policy

Having worked out how to make non-adherent primary cells amenable to microscopy, Allcyte GmbH has created a platform for imaging interactions between T cells and B cells that can predict drug responses in hematological cancers.

COO Nikolaus Krall said Allcyte’s approach of studying drug responses in both cancer and immune cells provides more accurate predictions of responses than methods that rely solely on cell lines or primary cancer cells. “Our cultures are as close to a recapitulation of a functional immune system as you could wish for. We can look at how cells talk to each other by measuring their physical interactions.”...